Gaurav Shah's Insider Trades & SAST Disclosures
Gaurav Shah's most recent trade in Rocket Pharmaceuticals Inc was a trade of 16,303 Common Stock done at an average price of $10.6 . Disclosure was reported to the exchange on Feb. 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gaurav Shah.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 10.58 per share. | 21 Feb 2025 | 16,303 | 772,680 (1%) | 0% | 10.6 | 172,486 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 243,345 | 243,345 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 81,655 | 788,983 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 13.05 per share. | 21 Nov 2024 | 11,091 | 707,328 (1%) | 0% | 13.1 | 144,782 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.50 per share. | 16 Aug 2024 | 9,650 | 718,419 (1%) | 0% | 18.5 | 178,564 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 67,785 | 737,859 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 67,785 | 0 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 23,940 | 670,074 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 23,940 | 0 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 23.35 per share. | 14 May 2024 | 9,790 | 728,069 (1%) | 0% | 23.4 | 228,597 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 9,683 | 646,134 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 9,683 | 67,785 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 7,979 | 636,451 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 7,979 | 23,940 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 196,336 | 196,336 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 66,577 | 621,339 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.84 per share. | 16 Feb 2024 | 20,272 | 554,762 (1%) | 0% | 29.8 | 604,876 | Common Stock |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 46,828 | 575,034 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 38,849 | 77,468 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 7,979 | 31,919 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.47 per share. | 17 Aug 2023 | 4,767 | 524,854 (0%) | 0% | 15.5 | 73,750 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 7,979 | 529,621 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 7,979 | 47,877 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.38 per share. | 17 May 2023 | 4,122 | 521,642 (0%) | 0% | 21.4 | 88,108 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 7,979 | 55,856 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 7,979 | 525,764 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 19.06 per share. | 17 Feb 2023 | 12,194 | 536,885 (0%) | 0% | 19.1 | 232,418 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 348,590 | 348,590 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 116,317 | 116,317 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 31,440 | 549,079 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 31,440 | 63,835 | - | - | Restricted Stock Units | |
| Talaris Therapeutics Inc | Gaurav Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 14,501 | 14,501 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 297,037 | 297,037 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 95,275 | 95,275 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Purchase of securities on an exchange or from another person at price $ 17.34 per share. | 07 Feb 2022 | 22,000 | 517,639 (0%) | 0% | 17.3 | 381,513 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.45 per share. | 31 Mar 2021 | 8,872 | 503,114 (0%) | 0% | 46.4 | 412,075 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.94 per share. | 31 Mar 2021 | 7,493 | 517,905 (0%) | 0% | 45.9 | 344,235 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.21 per share. | 31 Mar 2021 | 7,475 | 495,639 (0%) | 0% | 47.2 | 352,903 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.21 per share. | 31 Mar 2021 | 5,919 | 511,986 (0%) | 0% | 45.2 | 267,576 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 30 Mar 2021 | 75,880 | 612,751 (1%) | 0% | 1.7 | 128,237 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2021 | 75,880 | 0 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.24 per share. | 30 Mar 2021 | 61,350 | 548,401 (1%) | 0% | 44.2 | 2,714,320 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.86 per share. | 30 Mar 2021 | 48,732 | 545,376 (1%) | 0% | 43.9 | 2,137,152 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.06 per share. | 30 Mar 2021 | 23,003 | 525,398 (0%) | 0% | 45.1 | 1,036,557 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.80 per share. | 30 Mar 2021 | 19,984 | 614,092 (1%) | 0% | 41.8 | 835,329 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.80 per share. | 30 Mar 2021 | 8,667 | 594,108 (1%) | 0% | 42.8 | 370,906 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.34 per share. | 30 Mar 2021 | 8,505 | 536,871 (0%) | 0% | 44.3 | 377,105 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.59 per share. | 30 Mar 2021 | 3,000 | 609,751 (1%) | 0% | 45.6 | 136,770 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 185,000 | 185,000 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2020 | 90,925 | 0 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.43 per share. | 24 Mar 2020 | 90,925 | 1,061,642 (1%) | 0% | 0.4 | 39,098 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.78 per share. | 24 Mar 2020 | 32,645 | 1,028,997 (1%) | 0% | 13.8 | 449,848 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges